busulfan has been researched along with Metabolic Diseases in 4 studies
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Busulfan is a commonly used alkylating agent in the conditioning regimens of hematopoietic cell transplantation (HCT)." | 1.72 | Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis. ( Gupta, AO; Illamola, SM; Jennissen, CA; Long, SE; Long-Boyle, JR; Lund, TC; Orchard, PJ; Takahashi, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takahashi, T | 1 |
| Illamola, SM | 1 |
| Jennissen, CA | 1 |
| Long, SE | 1 |
| Lund, TC | 2 |
| Orchard, PJ | 2 |
| Gupta, AO | 1 |
| Long-Boyle, JR | 1 |
| Yabe, H | 1 |
| Gupta, A | 1 |
| Downey, M | 1 |
| Shanley, R | 1 |
| Jennissen, C | 1 |
| Miller, WP | 1 |
| Smith, AR | 1 |
| Skurikhin, EG | 1 |
| Pakhomova, AV | 1 |
| Pershina, OV | 1 |
| Ermolaeva, LA | 1 |
| Krupin, VA | 1 |
| Ermakova, NN | 1 |
| Pan, ES | 1 |
| Kudryashova, AI | 1 |
| Rybalkina, OY | 1 |
| Pavlovskaya, TB | 1 |
| Litvyakov, NV | 1 |
| Goldberg, VE | 1 |
| Dygai, AM | 1 |
1 review available for busulfan and Metabolic Diseases
| Article | Year |
|---|---|
Allogeneic hematopoietic stem cell transplantation for inherited metabolic disorders.
Topics: Activities of Daily Living; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation | 2022 |
3 other studies available for busulfan and Metabolic Diseases
| Article | Year |
|---|---|
Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis.
Topics: Body Weight; Busulfan; Child; Hematopoietic Stem Cell Transplantation; Humans; Metabolic Diseases; T | 2022 |
Reduced-Toxicity (BuFlu) Conditioning Is Better Tolerated but Has a Higher Second Transplantation Rate Compared to Myeloablative Conditioning (BuCy) in Children with Inherited Metabolic Disorders.
Topics: Busulfan; Child; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H | 2020 |
Regenerative Potential of Spermatogonial Stem Cells, Endothelial Progenitor Cells, and Epithelial Progenitor Cells of C57Bl/6 Male Mice with Metabolic Disorders.
Topics: Animals; Busulfan; CD24 Antigen; CD52 Antigen; Endothelial Progenitor Cells; Inflammation; Integrin | 2017 |